Private doctors join call for grace period, clarity over mandatory drug price display rule kicking in today
Its president Dr Shanmuganathan TV Ganeson said the government should instruct enforcement officers to adopt a non-punitive, educational approach during the initial period of implementation.
'The government should also engage GP (general practitioners) associations immediately to co-develop fair and workable compliance guidelines,' he said in a statement today.
The statement was issued in response to the unexpected gazettement of the mandatory medicine price display regulation under the Price Control and Anti-Profiteering Act 2011 (Act 723), which is scheduled to come into effect on May 1.
Dr Shanmuganathan said no grace period was provided under the gazetted regulation and this means that enforcement officers, particularly from the Ministry of Domestic Trade and Cost of Living, may initiate action against clinics immediately, based on their own interpretations of compliance.
He said the absence of an official implementation window or transitional directive had created a dangerous legal grey area.
'Frontline GP and specialist clinics, many of which serve B40 and M40 communities, are now legally exposed, despite making good faith efforts to adapt.
'Without time to restructure billing, train staff or engage patients, doctors face the risk of being wrongly penalised or accused of profiteering, simply for struggling to interpret and apply a complex new requirement,' he explained.
According to Dr Shanmuganathan, this regulation compels clinics to unbundle every aspect of care including consultation (per illness or complaint), medications (individually priced) as well as consumables, procedures, documentation and operational overheads.
He said this will result in longer and more itemised bills, which may be misinterpreted by patients as fee inflation, when in fact, the bundled subsidies clinics used to provide are no longer permitted.
As such, he advised all private clinics to begin itemising fees for consultation, medicine and services to the best of their ability and display medicine pricing in good faith, even partially, with clear explanations to patients.
He said they should keep records of all compliance efforts such as price lists, staff briefings and system changes and document any enforcement visits including names of officers, instructions given, and basis of alleged non-compliance.
He added that they should also report incidents to FPMPAM and state societies promptly for legal tracking and support.
Dr Shanmuganathan stressed that clinics should continue to act professionally, ethically and defensively, protecting both patients and staff while adapting under pressure.
'Doctors are not the cause of inflation, we are the first responders of Malaysia's health system,' he said.
He pledged that FPMPAM will continue to protect ethical practice, legal clarity and patient access in the face of regulatory overreach, adding: 'These are challenging times for GPs, especially. The struggle should be continued.' — The Borneo Post
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Barnama
6 days ago
- Barnama
MBSB IB Maintains Positive Call On Insurance Sector Despite Healthcare Inflation
-- Photograph for illustrative purposes MBSB IB Maintains Positive Call On Insurance Sector Despite Healthcare Inflation KUALA LUMPUR, Aug 15 (Bernama) -- MBSB Investment Bank (MBSB IB) has maintained its 'positive' recommendation on the insurance sector, citing attractive valuations and high dividend yields despite persistent healthcare inflation and delays in healthcare cost-control reforms. In a research note today, the bank said healthcare inflation remains a 'tricky issue to fix' as higher spending on the sector appears inevitable. 'Our primary concern is that if healthcare inflation is still rampant, what will happen at the end of Bank Negara Malaysia's three-year cap on medical insurance premium hikes? 'But there are multiple tailwinds -- a cheap price point, attractive dividend yields, a potential windfall in investment income, and encouraging progress by insurers in addressing the healthcare inflation problem -- making the sector due for a positive re-rating,' it said. The bank noted that companies under its coverage are market leaders, enabling them to withstand challenges better than most. MBSB IB said medical cost pressures are being fuelled by private hospitals rejecting proposed cost freezes, opposing pharmaceutical price controls, and what insurers describe as 'buffet table syndrome', where high claims are linked to increased service use without clear medical need. It also pointed to Malaysia's relatively low preventive healthcare spending and intensifying competition in healthcare tourism from Thailand, Indonesia and Singapore. However, the bank highlighted some progress in tackling medical inflation, including the Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025, which will require mandatory medicine price displays in the private sector by 2026. 'The initiative aims to enable the public to make informed choices by knowing the prices in advance and to encourage competitive medical pricing, although it has faced resistance, with several medical groups filing a judicial review," it said. The bank added that another factor is the decline in active pharmaceutical ingredient (API) raw material prices to pre-pandemic levels, after surging during the pandemic and staying elevated for several years due to logistical constraints, factory closures and increased demand for healthcare products. MBSB IB's top picks are Allianz Malaysia Bhd, with a target price of RM21.59, and Syarikat Takaful Malaysia Keluarga Bhd, with a target price of RM4.59, while LPI Capital Bhd is also rated 'buy'. -- BERNAMA
BusinessToday
6 days ago
- BusinessToday
Insurance Sector Poised For Healthy Gain Despite Inflation Worries
MBSB Investment Bank Bhd (MBSB Research) has maintained a POSITIVE call on the insurance sector, citing attractive valuations, solid dividend yields, and signs of progress in tackling healthcare inflation despite persistent headwinds. Allianz and Syarikat Takaful Malaysia Bhd (STMB) remain top picks with 'buy' recommendations and target prices of RM21.59 and RM4.59, respectively. The optimism comes even as the government once again postponed the mandatory rollout of the diagnosis-related groups (DRG) payment system for private hospitals, pushing the implementation from mid-2025 to 2027. The DRG framework, widely used in countries such as Thailand and Indonesia, aims to standardise hospital reimbursement based on diagnosis and treatment rather than charging per service. An interim version will begin in selected private hospitals this year, alongside a basic Medical and Health Takaful Insurance platform scheduled for 2026. Insurers have been taking firmer steps to address medical cost inflation, though MBSB noted that increased healthcare spending remains unavoidable. Malaysia's healthcare tourism industry is under competitive pressure from regional players such as Thailand and Singapore, with private hospitals investing heavily in high-end facilities to attract overseas patients. The Association of Private Hospitals Malaysia (APHM) has pushed back against several insurer proposals, including freezing private hospital costs for three years and regulating pharmaceutical prices, arguing these could compromise care standards and limit access to new treatments. Rising claims have also been attributed by APHM to more severe patient cases, potentially linked to post-pandemic complications. Preventive care remains a weak spot, with just 6–7% of the Health Ministry's budget allocated to prevention, far below the treatment allocation. Still, MBSB highlighted recent progress. The Price Control and Anti-Profiteering Order 2025 will require private sector medicine price displays by 2026, promoting transparency and competition. The cost of active pharmaceutical ingredients has also retreated to pre-pandemic levels, easing some pressure on drug prices. Furthermore, co-pay uptake is gaining traction, with Allianz reporting encouraging adoption rates and insurers seeing lower health loss ratios in early 2025. MBSB Research emphasised that while healthcare inflation is unlikely to disappear, continued insurer initiatives, combined with a low sector price point and the potential for higher investment income, provide a case for a positive re-rating. The firm noted that companies under its coverage are market leaders, better positioned to navigate economic uncertainty and the structural challenges of rising reinsurance costs. However, risks remain, including the possibility of slower premium growth if the economy weakens and the threat of persistent healthcare inflation even after the DRG rollout.
The Star
12-08-2025
- The Star
Compliance of drug price display rule at 55%, Dewan Rakyat told
KUALA LUMPUR: Checks during the first three months of enforcing drug price transparency showed that 55% of 1,639 private healthcare facilities nationwide complied satisfactorily, says Deputy Health Minister Lukanisman Awang Sauni. The remaining 45% had incomplete or inaccessible price displays, he added. ALSO READ: Drug price display order gazetted, to come into effect May 1 "These findings indicate the need for continued monitoring, guidance sessions and phased enforcement for non-compliant premises," he said during Minister's Question Time in the Dewan Rakyat on Tuesday (Aug 12). To ensure greater transparency and fairness in private healthcare pharmacy services, Lukanisman said the Health Ministry plans to conduct a comprehensive evaluation from September. "This aims to assess the impact of the drug pricing policy and guide improvements in the system. "It will inform (these) improvements to ensure transparency and fairness in private healthcare pharmacy services," he added. ALSO READ: Medicine price display rule to proceed on Aug 1, says Health Minister The display of drug prices, which came into effect on May 1 under the Price Control and Anti-Profiteering (Marking of Prices for Drugs) Order 2025, is part of the government's efforts to enhance public access to drug price information. This initiative seeks to ensure competitive pricing and informed consumer choices. From Aug 1, the ministry began inspections and monitoring, issuing warnings for non-compliance, with full enforcement and fines scheduled to commence on Jan 1. The phased approach aims to give private healthcare providers, including clinics, hospitals and community pharmacies, time to adjust and comply with the new regulations. The initiative faced some resistance from non-governmental organisations and medical associations, particularly concerning the regulation of consultation fees, which have not been reviewed for 30 years. ALSO READ: Medicine price display rule to stay However, Lukanisman noted that the ministry remains committed to inclusive engagement with stakeholders, including the Malaysian Medical Association, to address these issues and ensure a balanced approach to healthcare regulation. Addressing concerns raised by Jimmy Puah Wee Tse (PH-Tebrau) about rising medical costs, Lukanisman highlighted the ministry's ongoing efforts to implement interim Diagnosis-Related Group (DRG) systems in private facilities by 2027. "The DRG data will guide private facilities in setting reasonable prices, although it won't regulate profit margins," he said. DRG systems classify hospital cases with similar clinical characteristics and resource usage, allowing for a standardised payment system based on the diagnosis and treatment provided.
